Neva SGR

Asset management company of the Intesa Sanpaolo group that invests in biotechs.

Profile being verified

Stage
Series B to Series C across recorded rounds
Ticket
Tickets not disclosed; recorded rounds of CHF 26 M to USD 135 M
Location
Not specified
Tracked rounds
2

What they look for

Co-led the Series B extension of NUCLIDIUM; new investor in Nouscom's round. Mario Costantini, CEO and managing director, is quoted.

Recent investments

Recorded Swiss rounds: NUCLIDIUM (Series B, CHF 26 M, May 2026, co-lead), Nouscom (Series C, USD 135 M, October 2026).

Rounds tracked by FundSwiss